2.4 Pain, Agitation, & Delirium Management (PADIS)
Key Takeaways
- Implement 'analgesia-first' sedation universally: Always assess for and adequately treat underlying pain with analgesics before escalating sedative infusions.
- Propofol offers deep sedation and reliable amnesia with rapid offset, but zero analgesia; monitor strictly for hypotension and Propofol-Related Infusion Syndrome (PRIS).
- Dexmedetomidine provides unique rousable, cooperative sedation without respiratory depression, but clinicians must monitor closely for dose-dependent bradycardia.
- Benzodiazepines must be strictly avoided for routine continuous sedation due to their profound association with prolonged delirium and delayed ventilator weaning.
- Antipsychotics (like haloperidol) do not cure or shorten delirium; they are strictly a temporary chemical restraint for severe, dangerous hyperactive agitation.
Pain, Agitation, Delirium, Immobility, and Sleep (PADIS)
The PADIS Framework: Paradigm Shift in Critical Care
The integrated management of Pain, Agitation/sedation, Delirium, Immobility, and Sleep disruption (collectively termed the PADIS guidelines) forms the absolute core of humane, modern, high-quality critical care. The Society of Critical Care Medicine (SCCM) vigorously advocates for an integrated, patient-centered approach. This involves systematically assessing and treating pain prior to any sedation (an "analgesia-first" or "analgosedation" strategy), meticulously avoiding deep sedation whenever possible, rigorously performing daily spontaneous awakening trials (SATs), routinely screening for and mitigating delirium, and aggressively promoting early mobilization.
Pain Assessment and Multimodal Management
Pain is a universally prevalent stressor in the ICU. Uncontrolled pain triggers severe sympathetic nervous system hyperactivation, leading to tachycardia, increased myocardial oxygen consumption, systemic vasoconstriction, impaired wound healing, and it is a massive independent risk factor for the development of delirium.
Rigorous Assessment: Patient self-reporting remains the gold standard of pain assessment. However, for intubated, critically ill, or non-communicative patients, the use of validated behavioral scales is mandatory. The Behavioral Pain Scale (BPS) and the Critical-Care Pain Observation Tool (CPOT) are the most highly validated, reliable tools available. A CPOT score greater than 2 or a BPS score greater than 5 definitively indicates clinically significant pain demanding immediate pharmacological or physical intervention.
Advanced Pharmacotherapy:
- Intravenous Opioids: Fentanyl, morphine, and hydromorphone remain the absolute mainstay for managing severe acute ICU pain. Fentanyl offers a rapid onset and short clinical duration due to its highly lipophilic nature, and crucially, it does not cause histamine release, making it hemodynamically neutral in unstable shock states. Morphine has a longer duration of action but can provoke significant histamine release (leading to vasodilation and hypotension) and its active metabolites dangerously accumulate in acute kidney injury. Hydromorphone (Dilaudid) is significantly more potent than morphine and lacks active renal metabolites, making it the preferred, safer choice in patients with severe renal impairment.
- Non-Opioid Multimodal Adjuncts: A multimodal approach is essential to maximize analgesia while actively minimizing total opioid requirements and their associated side effects (ileus, respiratory depression, tolerance). Intravenous acetaminophen, low-dose ketamine infusions (providing NMDA receptor antagonism), gabapentin or pregabalin (highly effective for neuropathic pain), and dexmedetomidine all serve as powerful, evidence-based opioid-sparing adjuncts.
Strategic Agitation and Sedation Management
Agitation in the ICU can violently endanger patients through unintended device or line removal, and dangerous patient-ventilator dyssynchrony. However, the historical practice of routine, deep continuous sedation drastically prolongs mechanical ventilation duration, exponentially increases the risk of delirium, causes profound diaphragmatic atrophy, and worsens long-term mortality.
Targeted Assessment: The Richmond Agitation-Sedation Scale (RASS) or the Sedation-Agitation Scale (SAS) must be utilized for continuous titration. The modern, evidence-based target RASS is 0 (alert and calm) to -1 (drowsy), unless deep, unarousable sedation is explicitly medically required (e.g., severe ARDS requiring neuromuscular blockade, elevated intracranial pressure, or refractory status epilepticus).
Sedative Pharmacotherapy:
- Propofol: A highly lipophilic, potent GABA-A receptor agonist. It boasts an incredibly rapid onset and rapid offset (when infusion is stopped), allowing for prompt and reliable daily neurological examinations (SATs). It provides robust sedation and profound amnesia, but crucially, it provides zero analgesia. Severe complications include dose-dependent hypotension (due to direct vasodilation and myocardial depression), profound respiratory depression, hypertriglyceridemia, and the rare but fatal Propofol-Related Infusion Syndrome (PRIS).
- Dexmedetomidine (Precedex): A highly selective central alpha-2 adrenergic agonist. It uniquely provides a state of "cooperative sedation," where patients are resting but easily arousable and capable of following commands. It also offers mild to moderate analgesia and, uniquely among sedatives, does not induce clinically significant respiratory depression, making it ideal for facilitating the extubation process. The primary dose-limiting adverse effects are marked bradycardia and systemic hypotension.
- Benzodiazepines (Midazolam, Lorazepam): Potent GABA agonists that provide deep, highly reliable sedation, amnesia, and anxiolysis. However, they are highly deliriogenic. They possess prolonged, highly unpredictable half-lives, particularly in patients suffering from concurrent renal or hepatic dysfunction, leading to massive drug accumulation. Modern SCCM guidelines strongly recommend against utilizing benzodiazepines for routine, continuous ICU sedation, strictly reserving their use for alcohol withdrawal syndromes, refractory status epilepticus, or cases where deep sedation is mandated and all other agents have utterly failed.
Delirium: Assessment, Prevention, and Management
ICU Delirium is an acute, fluctuating disturbance in mental status characterized by profound inattention, disorganized thinking, and altered levels of consciousness. It is a massive, independent predictor of significantly increased 6-month mortality, prolonged ICU and hospital length of stay, and devastating long-term cognitive impairment (Post-Intensive Care Syndrome - PICS).
Mandatory Assessment: Routine, protocolized screening using the Confusion Assessment Method for the ICU (CAM-ICU) or the Intensive Care Delirium Screening Checklist (ICDSC) is an absolute standard of care. The CAM-ICU specifically assesses for four features: acute mental status change or fluctuation, inattention, altered level of consciousness, and disorganized thinking.
Comprehensive Management: The absolute foundation of delirium management is rigorous prevention and relentless non-pharmacologic intervention, beautifully encapsulated in the ABCDEF bundle. This comprehensively includes: Awakening and Breathing Coordination (pairing daily SATs with SBTs), Careful Choice of analgesia/sedation (avoiding benzos), Delirium monitoring, Early mobility, and Family engagement. Ensuring sensory optimization (glasses, hearing aids), frequent reorientation, and aggressively promoting normal sleep-wake circadian rhythms are critical.
Pharmacologic treatment of delirium remains highly controversial and largely ineffective. There is currently no FDA-approved medication for the prevention or treatment of ICU delirium. Atypical and typical antipsychotics (e.g., haloperidol, quetiapine, olanzapine) do not prevent delirium, they do not cure it, nor do they reduce the overall duration of delirium. They are strictly indicated only for short-term symptom control to manage severe, hyperactive agitation that poses an immediate, physical threat to the patient (e.g., self-extubation) or to the clinical staff. When utilizing antipsychotics, continuous telemetry monitoring of the QTc interval is absolutely required due to the potentially fatal risk of inducing Torsades de Pointes.
Clinical Quick Reference: PADIS Assessment Scales
| Clinical Domain | Gold Standard Validated Assessment Tools | Evidence-Based Target / Goal |
|---|---|---|
| Pain | Patient report, BPS, CPOT | CPOT ≤ 2, BPS ≤ 5 |
| Agitation / Sedation | RASS, SAS | RASS 0 to -1 (unless deep sedation explicitly indicated) |
| Delirium | CAM-ICU, ICDSC | CAM-ICU Negative / ICDSC < 4 |
Immobility and Sleep Disruption
Early, aggressive physical mobility is the single most powerful intervention consistently proven in clinical trials to reduce both the incidence and duration of ICU delirium. Physical and occupational therapy should commence as soon as the patient is hemodynamically stable, routinely including patients who remain intubated on mechanical ventilation. Sleep disruption in the critical care environment is profound and universally experienced due to incessant alarms, bright lighting, and frequent nocturnal nursing interventions. Mitigation strategies include implementing strict noise reduction protocols, bundling care to minimize nighttime interruptions, and utilizing atypical agents like melatonin to attempt to restore natural circadian rhythms.
A 66-year-old intubated patient is highly agitated, bucking the ventilator, and actively pulling at their central line. Their current RASS is +3. The nurse reports their CPOT score is 5, indicating significant active pain. According to the foundational PADIS guidelines, what is the most appropriate and effective initial intervention?
A mechanically ventilated patient with a complex history of severe COPD exacerbation is being considered for a continuous sedative infusion to maintain a light target RASS of -1. The AGACNP desperately wishes to utilize a medication that will not cause respiratory depression, allowing the patient to fully participate in spontaneous breathing trials. Which agent is the optimal pharmacological choice?
Which of the following classes of medications is most strongly and consistently associated with an exponential increase in the risk of developing severe ICU delirium, and therefore should be strictly avoided for routine continuous sedation?